Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 1
Submit an article Journal homepage
316
Views
9
CrossRef citations to date
0
Altmetric
Letters to the Editor

Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series

David H. VesoleJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; Correspondence[email protected]
View further author information
,
Joshua RichterJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; View further author information
,
Noa BiranJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; View further author information
,
Laura McBrideJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; View further author information
,
Palka AnandJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; View further author information
,
Mei HuangAmgen Inc., Thousand Oaks, CA, USAView further author information
,
Anita-Zahlten KumeliAmgen Inc., Thousand Oaks, CA, USAView further author information
,
Zandra KlippelAmgen Inc., Thousand Oaks, CA, USAView further author information
,
Karim IskanderAmgen Inc., Thousand Oaks, CA, USAView further author information
&
David S. SiegelJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; View further author information
 show all
Pages 259-261 | Received 26 Jan 2017, Accepted 14 Apr 2017, Published online: 05 Jun 2017
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1321749

Additional information

Funding

The PX-171-007 study was supported by Onyx Pharmaceuticals, an Amgen subsidiary. Medical writing assistance was provided by BlueMomentum, an Ashfield Company, and funded by Amgen Inc.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.